RU2002133458A - Compounds of piperazine and piperidine - Google Patents

Compounds of piperazine and piperidine

Info

Publication number
RU2002133458A
RU2002133458A RU2002133458/04A RU2002133458A RU2002133458A RU 2002133458 A RU2002133458 A RU 2002133458A RU 2002133458/04 A RU2002133458/04 A RU 2002133458/04A RU 2002133458 A RU2002133458 A RU 2002133458A RU 2002133458 A RU2002133458 A RU 2002133458A
Authority
RU
Russia
Prior art keywords
compound according
alkyl
compound
compounds
hydrogen
Prior art date
Application number
RU2002133458/04A
Other languages
Russian (ru)
Other versions
RU2261250C2 (en
Inventor
Рулоф В. Фенстра
ДЕР ХЕЙДЕН Йоханнес А. М. ВАН
Корнелис Г. Крюсе
Стефен К. ЛОНГ
СХАРРЕНБЮРГ Густаф Й. М. ВАН
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of RU2002133458A publication Critical patent/RU2002133458A/en
Application granted granted Critical
Publication of RU2261250C2 publication Critical patent/RU2261250C2/en

Links

Claims (10)

1. Соединения формулы (I)1. The compounds of formula (I)
Figure 00000001
Figure 00000001
 где Y является водородом, галогеном, С1-С3-алкилом или CN, CF3, OCF3, SCF3, С1-С3-алкоксигруппой, аминогруппой или моно- или ди(С1-С3-алкил)замещенной аминогруппой или гидроксигруппой;where Y is hydrogen, halogen, C 1 -C 3 -alkyl or CN, CF 3 , OCF 3 , SCF 3 , C 1 -C 3 -alkoxy, amino or mono- or di (C 1 -C 3 -alkyl) substituted an amino group or a hydroxy group; Х является O, S, SO или SO2;X is O, S, SO or SO 2 ; Z представляет -C,=C, -N;Z is —C, = C, —N; R1 и R2 независимо представляют водород или С1-С3-алкил;R 1 and R 2 independently represent hydrogen or C 1 -C 3 alkyl; Q является бензилом или 2-, 3- или 4-пиридилметилом, группы которых могут быть замещены одним или более заместителями, выбранными из группы, содержащей галоген, нитро, циано, моно- или ди(С1-С3-алкил)аминогруппу, С1-С3-алкоксигруппу, CF3, OCF3, SCF3, С1-С4-алкил, С1-С3-алкилсульфонил или гидроксигруппу,Q is benzyl or 2-, 3- or 4-pyridylmethyl, the groups of which can be substituted with one or more substituents selected from the group consisting of halogen, nitro, cyano, mono- or di (C 1 -C 3 -alkyl) amino group, A C 1 -C 3 alkoxy group, CF 3 , OCF 3 , SCF 3 , C 1 -C 4 alkyl, C 1 -C 3 alkylsulfonyl or a hydroxy group, а также их соли и пролекарства.as well as their salts and prodrugs. 2. Соединения по п.1, где Y, R1 и R2 являются водородом, Х представляет кислород, Q является (замещенным) бензилом и Z имеет значения, указанные в п.1.2. The compounds of claim 1, wherein Y, R 1, and R 2 are hydrogen, X is oxygen, Q is (substituted) benzyl, and Z is as defined in claim 1. 3. Соединения по п.2, где Q является бензилом, а Z представляет -N.3. The compound of claim 2, wherein Q is benzyl and Z is —N. 4. Способ получения соединений по п.1 взаимодействием соединения формулы (I), в котором Q является водородом, с соединением Q-Hal, в котором Q имеет значения, указанные в п.1, и Hal является галогеном.4. The method for producing compounds according to claim 1 by reacting a compound of formula (I) in which Q is hydrogen with a Q-Hal compound in which Q is as defined in claim 1, and Hal is halogen. 5. Фармацевтическая композиция, содержащая, по меньшей мере, одно соединение по п.1 в качестве активного компонента.5. A pharmaceutical composition containing at least one compound according to claim 1 as an active component. 6. Способ получения фармацевтической композиции, отличающийся тем, что соединение по п.1 приводят в форму пригодную для введения.6. A method of obtaining a pharmaceutical composition, characterized in that the compound according to claim 1 is brought into a form suitable for administration. 7. Способ лечения нарушений центральной нервной системы, отличающийся тем, что используют соединение по п.1.7. A method of treating disorders of the central nervous system, characterized in that the compound according to claim 1 is used. 8. Способ лечения состояния страха и/или депрессии, отличающийся тем, что используют соединение по п.1.8. A method of treating a state of fear and / or depression, characterized in that the compound according to claim 1 is used. 9. Способ лечения болезни Паркинсона, отличающийся тем, что используют соединение по п.1.9. A method of treating Parkinson's disease, characterized in that the compound according to claim 1 is used. 10. Способ лечения наркомании (алкоголизма), отличающийся тем, что используют соединение, заявленное по п.1.10. A method for the treatment of drug addiction (alcoholism), characterized in that the compound according to claim 1 is used.
RU2002133458/04A 2000-05-12 2001-05-10 Piperazine and piperidine compounds RU2261250C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00201699,6 2000-05-12
EP00201699 2000-05-12

Publications (2)

Publication Number Publication Date
RU2002133458A true RU2002133458A (en) 2004-08-20
RU2261250C2 RU2261250C2 (en) 2005-09-27

Family

ID=8171488

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002133458/04A RU2261250C2 (en) 2000-05-12 2001-05-10 Piperazine and piperidine compounds

Country Status (28)

Country Link
US (2) US6911448B2 (en)
EP (1) EP1283838B1 (en)
JP (1) JP2003532729A (en)
CN (1) CN1174979C (en)
AR (1) AR028443A1 (en)
AT (1) ATE255578T1 (en)
AU (2) AU6392701A (en)
BR (1) BR0110592A (en)
CA (1) CA2405971C (en)
CZ (1) CZ301464B6 (en)
DE (1) DE60101386T2 (en)
DK (1) DK1283838T3 (en)
DZ (1) DZ3370A1 (en)
ES (1) ES2211809T3 (en)
HK (1) HK1055952A1 (en)
HU (1) HUP0302016A2 (en)
IL (2) IL152177A0 (en)
MX (1) MXPA02011084A (en)
NO (1) NO323778B1 (en)
NZ (1) NZ522116A (en)
PL (1) PL198857B1 (en)
PT (1) PT1283838E (en)
RU (1) RU2261250C2 (en)
SK (1) SK286778B6 (en)
TR (1) TR200302294T4 (en)
UA (1) UA72337C2 (en)
WO (1) WO2001085725A1 (en)
ZA (1) ZA200208537B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532729A (en) * 2000-05-12 2003-11-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Piperazine and piperidine compounds
CA2453837C (en) * 2001-07-20 2011-10-04 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder using eltoprazine and related compounds
AU2003244160A1 (en) * 2002-06-25 2004-01-06 Sumitomo Pharmaceuticals Co., Ltd. Novel benzoxazolinone derivative
ES2232292B1 (en) * 2003-07-30 2006-11-01 Laboratorios Del Dr. Esteve, S.A. SULFONAMIDIC COMPOUNDS DERIVED FROM BENZOXAZINONA, ITS PREPARATION AND USE AS MEDICATIONS.
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
EP1595542A1 (en) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
AR058022A1 (en) * 2005-08-22 2008-01-23 Solvay Pharm Bv DERIVATIVES OF BENZOOXAZOLES, PHARMACEUTICAL COMPOSITIONS AND ITS USE FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS.
CA2621158A1 (en) * 2005-08-22 2007-03-01 Solvay Pharmaceuticals B.V. N-oxides as prodrugs of piperazine & piperidine derivatives
US7750013B2 (en) 2005-08-22 2010-07-06 Solvay Pharmaceuticals, B.V. N-oxides as prodrugs of piperazine and piperidine derivatives
US20070275977A1 (en) * 2006-05-02 2007-11-29 Van Aar Marcel P N-oxides of pyridylmethyl -piperazine and -piperidine derivatives
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
WO2008068185A1 (en) 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
AU2007329066B2 (en) 2006-12-07 2012-04-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
WO2008068183A1 (en) 2006-12-08 2008-06-12 F. Hoffmann-La Roche Ag Indoles
US20080139618A1 (en) 2006-12-08 2008-06-12 Caterina Bissantz Indoles
EP2097376A2 (en) 2006-12-22 2009-09-09 F. Hoffmann-Roche AG Spiro-piperidine derivatives
AU2009204851A1 (en) * 2008-01-15 2009-07-23 Abbott Healthcare Products B.V. Bifeprunox derivatives
AU2017315947B2 (en) 2016-08-26 2022-12-01 Exciva GmbH Compositions and methods thereof
EP3831898A4 (en) * 2018-07-27 2022-04-06 Chugoku Marine Paints, Ltd. Antifouling paint composition, antifouling coating, substrate with antifouling coating, ?production method thereof, and repair method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126275A (en) * 1983-12-13 1985-07-05 Otsuka Pharmaceut Co Ltd Benzothiazole derivative
FR2567884B1 (en) 1984-07-19 1987-03-06 Roussel Uclaf NEW INDOLE DERIVATIVES, THEIR PREPARATION, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
ATE81975T1 (en) * 1984-12-21 1992-11-15 Duphar Int Res MEDICATIONS WITH PSYCHOTROPIC EFFECTS.
ATE44528T1 (en) 1984-12-21 1989-07-15 Duphar Int Res MEDICATIONS WITH ANTIPSYCHOTIC EFFECTS.
HU227454B1 (en) * 1996-03-29 2011-06-28 Duphar Int Res Piperazine and piperidine compounds, process for their preparation and pharmaceutical compositions containing the same
GB9811879D0 (en) * 1998-06-03 1998-07-29 Knoll Ag Therapeutic agents
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
JP2003532729A (en) * 2000-05-12 2003-11-05 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Piperazine and piperidine compounds
CA2405758A1 (en) * 2000-05-12 2001-11-15 Solvay Pharmaceuticals B.V. Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders

Similar Documents

Publication Publication Date Title
RU2002133458A (en) Compounds of piperazine and piperidine
RU2324684C2 (en) Pyrimidine derivatives
RU2003132687A (en) TREATMENT OF TYPE 2 DIABETES BY DIPEPTIDYLPEPTIDASE IV INHIBITORS
RU2002118705A (en) 4-AMINOPIPERIDINE DERIVATIVES AND THEIR APPLICATION AS A MEDICINE
WO2006034833A1 (en) Cyclic diarly ureas suitable as tyrosine kinase inhibitors
RU2003116648A (en) SUBSTITUTED IMIDAZOPYRIDINES
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
NZ528851A (en) N-aroyl cyclic amines
CA2396590A1 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
RU2001116117A (en) NEW PIPERAZINE AND PIPERIDINE COMPOUNDS
RU2011103234A (en) NEW PHENYLPYRAZINONES AS KINASE INHIBITORS
RU2007111758A (en) AMINO DERIVATIVES 7- AMINO-3-Phenyldihydropyrimido [4,5-D] PYRIMIDINONES, THEIR PRODUCTION AND APPLICATION AS PROTEINKINASE INHIBITORS
RU2007128085A (en) QUALITY AMMONIUM SALTS AS AN M3 ANTAGONISTS
JP2002508347A5 (en)
BR0008979A (en) Chemical compound, use of a compound, method of treatment, process of preparing a compound, pharmaceutical composition and method of manufacturing it
JP2005511698A5 (en)
HU191643B (en) Process for preparing new n-phenyl-n'-cycloalkyl-alkanoyl-piperazine derivatives
RU2007128080A (en) Pyrrolidinium derivatives as muscarinic receptors of the Ministry of Health
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
RU2004100302A (en) AMRIDES OF ANTHRANILIC ACID WITH A HETEROARYL SULPHONILY LATERAL CHAIN, METHOD FOR PRODUCING THEM, THEIR APPLICATION AS A MEDICINAL OR DIAGNOSTIC MEDICINE, AND ALSO CONTAINED
RU2007125659A (en) Phenylpiperazine derivatives combining the properties of incomplete agonism to dopamine-D2 receptors and inhibition of reuptake of serotonin
RU2002125495A (en) HYDROXYPHENYL-PIPERIDIN-4-YLIDEN-METHYL-BENZAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN
RU2008110945A (en) N-OXIDES AS MEDICINES OF PIPERASIN AND PIPERIDINE DERIVATIVES
ATE361918T1 (en) 4-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA AND ITS USE IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE-3 (GSK3)-ASSOCIATED CONDITIONS
JP2002529497A5 (en)